{"id":1927,"date":"2011-10-01T01:00:00","date_gmt":"2011-10-01T00:00:00","guid":{"rendered":"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/"},"modified":"2018-10-20T18:40:01","modified_gmt":"2018-10-20T16:40:01","slug":"epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh","status":"publish","type":"post","link":"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/","title":{"rendered":"Epid\u00e9miologie clinique de l\u2019h\u00e9patite virale delta (VHD) en France : r\u00e9sultats de l\u2019observatoire de l\u2019h\u00e9patite Delta des p\u00f4les de r\u00e9f\u00e9rences et de l\u2019ANGH."},"content":{"rendered":"<p><strong>2011<\/strong><\/p>\n<p><em>P. Renard (1), C. Castelneau (2), N. Ganne  (3), J. Gournay (4), S. Pol (5), J.D. Grange (6), C. Eug\u00e8ne (7), J. Denis ((1) H\u00f4pital V Dupouy Argenteuil, (2) H\u00f4pital Beaujon Clichy, (3) H\u00f4pital Jean Verdier Bondy, (4) CHU Nantes, (5) H\u00f4pital Cochin Paris, (6) H\u00f4pital Tenon Paris, (7) H\u00f4pital de Poissy, (8) H\u00f4pital Sud Francilien Evry.8) , P ; Marcellin (2) pour la F\u00e9d\u00e9ration des P\u00f4les de R\u00e9f\u00e9rence pour les H\u00e9patites et L\u2019ANGH.<\/em><\/p>\n<p><strong>H\u00e9patologie <\/strong>&#8211; \u00a02011-05-13 &#8211;\u00a0CO &#8211;<\/p>\n<p>________________________________<\/p>\n<p>L\u2019h\u00e9patite virale Delta (VHD) est une affection compliquant l\u2019h\u00e9patite chronique virale B. Elle est peu fr\u00e9quente. Nous avons voulu conna\u00eetre par une \u00e9tude observationelle son \u00e9pid\u00e9miologie. De 2006 \u00e0 2008, les services d\u2019h\u00e9patologie volontaires de la f\u00e9d\u00e9ration des poles de r\u00e9f\u00e9rences des h\u00e9patites et de l\u2019ANGH ont recens\u00e9 tous les malades porteurs du VHD vus en consultations ou en hospitalisation. Les donn\u00e9es \u00e9pid\u00e9miologioques, cliniques biologiques histopathologiques virologiques et th\u00e9rapeutiques \u00e9taient recueillies.<br \/>\nR\u00e9sultats : 188 malades provenant de 22 centres ont \u00e9t\u00e9 inclus. 111 (59%) malades provenaient de 4 h\u00f4pitaux. 67% des malades \u00e9taient des hommes, 35% caucasiens et 56% d\u2019origine Africaine. L\u2019\u00e2ge moyen \u00e9tait de 34\u00b19 ans, l\u2019IMC moyen \u00e9tait de 23.2\u00b13.9kg\/m\u00b2, 22% des malades d\u00e9claraient consommer + de 30 g d\u2019alcool par jour. L\u2019origine retenue : end\u00e9mique ou familiale 57%, toxicomanie 26%, post transfusionelle 7%, sexuelle 3%, inconnue 7%. Biologiquement, les ALAT \u00e9taient \u00e0 2.0\u00b1 1.9*N, l\u2019IgM VHD + chez 67.9% des 128 malades chez qui elle a \u00e9t\u00e9 recherch\u00e9e. L\u2019ARN VHD recherch\u00e9 chez 153 malades \u00e9tait positif  chez 114 (74.5%), la charge VHD \u00e9tait \u00e0 5.4\u00b11.5log. 118 (62%)  avaient un HBVDNA non d\u00e9tectable, 38% un HBVDNA positif \u00e0 4.0\u00b1 1.3log, 21 : 11.6% avaient un AgHBe +. 44 malades sur 164 test\u00e9s (26.8%) \u00e9taient HCV +, 21 sur 170 test\u00e9s (12.3%) \u00e9taient HIV+ dont 8 sur 164 (5%) \u00e9taient co-infect\u00e9s VHC + VIH. L\u2019histologie \u00e9tait disponibles pour 141 patients : 49 (34.8%) \u00e9taient F4 \u00e2ge moyen 42.8\u00b18.4 ans, 29 (20.5%) F3, 44 (31.2%) F2, 19 (13.5%) F0 ou F1 ; l\u2019activit\u00e9 \u00e0 2.05\u00b10.79 en Metavir. Enfin 5 (2.6%) malades \u00e9taient porteur d\u20191 CHC \u00e2ge moyen 51.8 ans (39-70). 115 patients avaient re\u00e7u ou recevaient un traitement : 22 (19%) par Interferon standard, 85 (74%) par Interferon p\u00e9gyl\u00e9 (IFNPEG) et 8 (7%) par analogues. Une r\u00e9ponse virologique ou biochimique \u00e9tait observ\u00e9e dans 44% des cas en fin de traitement. L\u2019absence IgM VHD \u00e9tait associ\u00e9e \u00e0 la r\u00e9ponse en fin de traitement 84% vs 45% (p=0.01). Les malades F3, F4 r\u00e9pondaient moins que ceux F1, F2 40% vs 60% (NS). Le taux d\u2019ARN, le sexe, l\u2019\u00e2ge, la co-infection VHC ou VIH les taux d\u2019ALAT ou d\u2019HBVDNA ou le score histologique d\u2019activit\u00e9 n\u2019influen\u00e7aient pas la r\u00e9ponse en fin de traitement. 22(19.1%) des malades trait\u00e9s gardaient un ARNVHD \u2013 6 mois apr\u00e8s la fin du traitement (SVR) dont 15 sur 50 (30%) qui avaient \u00e9t\u00e9s trait\u00e9s par IFNPEG.<br \/>\nEn conclusion : dans cette large s\u00e9rie d\u2019h\u00e9patite chronique Delta fran\u00e7aise, cette maladie appara\u00eet peu fr\u00e9quente, s\u00e9v\u00e8re 35% de cirrhose, chez des malades jeunes \u00e2ge moyen 42.8 ans. Un traitement est le plus souvent propos\u00e9 : L\u2019IFNPEG entra\u00eene une SVR dans 30% des cas. L\u2019ARNVHD \u00e9tait n\u00e9gatif chez 44% des malades en fin de traitement.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>2011 P. Renard (1), C. Castelneau (2), N. Ganne (3), J. Gournay (4), S. Pol (5), J.D. Grange (6), C. Eug\u00e8ne (7), J. Denis ((1) H\u00f4pital V Dupouy Argenteuil, (2) H\u00f4pital Beaujon Clichy, (3) H\u00f4pital Jean Verdier Bondy, (4) CHU Nantes, (5) H\u00f4pital Cochin Paris, (6) H\u00f4pital Tenon Paris, (7) H\u00f4pital de Poissy, (8) H\u00f4pital [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[3],"tags":[22],"class_list":["post-1927","post","type-post","status-publish","format-standard","hentry","category-hepatologie","tag-22"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Epid\u00e9miologie clinique de l\u2019h\u00e9patite virale delta (VHD) en France : r\u00e9sultats de l\u2019observatoire de l\u2019h\u00e9patite Delta des p\u00f4les de r\u00e9f\u00e9rences et de l\u2019ANGH. - Abstracts des congr\u00e8s de l&#039;ANGH<\/title>\n<meta name=\"description\" content=\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Epid\u00e9miologie clinique de l\u2019h\u00e9patite virale delta (VHD) en France : r\u00e9sultats de l\u2019observatoire de l\u2019h\u00e9patite Delta des p\u00f4les de r\u00e9f\u00e9rences et de l\u2019ANGH. - Abstracts des congr\u00e8s de l&#039;ANGH\" \/>\n<meta property=\"og:description\" content=\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\" \/>\n<meta property=\"og:url\" content=\"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/\" \/>\n<meta property=\"og:site_name\" content=\"Abstracts des congr\u00e8s de l&#039;ANGH\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ANGH-2136322560030484\/\" \/>\n<meta property=\"article:published_time\" content=\"2011-10-01T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-10-20T16:40:01+00:00\" \/>\n<meta name=\"author\" content=\"abstracts\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"abstracts\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/\"},\"author\":{\"name\":\"abstracts\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1\"},\"headline\":\"Epid\u00e9miologie clinique de l\u2019h\u00e9patite virale delta (VHD) en France : r\u00e9sultats de l\u2019observatoire de l\u2019h\u00e9patite Delta des p\u00f4les de r\u00e9f\u00e9rences et de l\u2019ANGH.\",\"datePublished\":\"2011-10-01T00:00:00+00:00\",\"dateModified\":\"2018-10-20T16:40:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/\"},\"wordCount\":539,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\"},\"keywords\":[\"2011\"],\"articleSection\":[\"Hepatologie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/\",\"url\":\"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/\",\"name\":\"Epid\u00e9miologie clinique de l\u2019h\u00e9patite virale delta (VHD) en France : r\u00e9sultats de l\u2019observatoire de l\u2019h\u00e9patite Delta des p\u00f4les de r\u00e9f\u00e9rences et de l\u2019ANGH. - Abstracts des congr\u00e8s de l&#039;ANGH\",\"isPartOf\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#website\"},\"datePublished\":\"2011-10-01T00:00:00+00:00\",\"dateModified\":\"2018-10-20T16:40:01+00:00\",\"description\":\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\",\"breadcrumb\":{\"@id\":\"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/angh.net\/abstracts\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Epid\u00e9miologie clinique de l\u2019h\u00e9patite virale delta (VHD) en France : r\u00e9sultats de l\u2019observatoire de l\u2019h\u00e9patite Delta des p\u00f4les de r\u00e9f\u00e9rences et de l\u2019ANGH.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/angh.net\/abstracts\/#website\",\"url\":\"https:\/\/angh.net\/abstracts\/\",\"name\":\"Abstracts des congr\u00e8s de l&#039;ANGH\",\"description\":\"Base de donn\u00e9es des abstracts du congr\u00e8s depuis 2003\",\"publisher\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/angh.net\/abstracts\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\",\"name\":\"ANGH\",\"url\":\"https:\/\/angh.net\/abstracts\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg\",\"contentUrl\":\"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg\",\"width\":48,\"height\":18,\"caption\":\"ANGH\"},\"image\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ANGH-2136322560030484\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1\",\"name\":\"abstracts\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g\",\"caption\":\"abstracts\"},\"url\":\"https:\/\/angh.net\/abstracts\/author\/abstracts\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Epid\u00e9miologie clinique de l\u2019h\u00e9patite virale delta (VHD) en France : r\u00e9sultats de l\u2019observatoire de l\u2019h\u00e9patite Delta des p\u00f4les de r\u00e9f\u00e9rences et de l\u2019ANGH. - Abstracts des congr\u00e8s de l&#039;ANGH","description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/","og_locale":"fr_FR","og_type":"article","og_title":"Epid\u00e9miologie clinique de l\u2019h\u00e9patite virale delta (VHD) en France : r\u00e9sultats de l\u2019observatoire de l\u2019h\u00e9patite Delta des p\u00f4les de r\u00e9f\u00e9rences et de l\u2019ANGH. - Abstracts des congr\u00e8s de l&#039;ANGH","og_description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","og_url":"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/","og_site_name":"Abstracts des congr\u00e8s de l&#039;ANGH","article_publisher":"https:\/\/www.facebook.com\/ANGH-2136322560030484\/","article_published_time":"2011-10-01T00:00:00+00:00","article_modified_time":"2018-10-20T16:40:01+00:00","author":"abstracts","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"abstracts","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/#article","isPartOf":{"@id":"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/"},"author":{"name":"abstracts","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1"},"headline":"Epid\u00e9miologie clinique de l\u2019h\u00e9patite virale delta (VHD) en France : r\u00e9sultats de l\u2019observatoire de l\u2019h\u00e9patite Delta des p\u00f4les de r\u00e9f\u00e9rences et de l\u2019ANGH.","datePublished":"2011-10-01T00:00:00+00:00","dateModified":"2018-10-20T16:40:01+00:00","mainEntityOfPage":{"@id":"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/"},"wordCount":539,"commentCount":0,"publisher":{"@id":"https:\/\/angh.net\/abstracts\/#organization"},"keywords":["2011"],"articleSection":["Hepatologie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/","url":"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/","name":"Epid\u00e9miologie clinique de l\u2019h\u00e9patite virale delta (VHD) en France : r\u00e9sultats de l\u2019observatoire de l\u2019h\u00e9patite Delta des p\u00f4les de r\u00e9f\u00e9rences et de l\u2019ANGH. - Abstracts des congr\u00e8s de l&#039;ANGH","isPartOf":{"@id":"https:\/\/angh.net\/abstracts\/#website"},"datePublished":"2011-10-01T00:00:00+00:00","dateModified":"2018-10-20T16:40:01+00:00","description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","breadcrumb":{"@id":"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/angh.net\/abstracts\/epidemiologie-clinique-de-lhepatite-virale-delta-vhd-en-france-resultats-de-lobservatoire-de-lhepatite-delta-des-poles-de-references-et-de-langh\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/angh.net\/abstracts\/"},{"@type":"ListItem","position":2,"name":"Epid\u00e9miologie clinique de l\u2019h\u00e9patite virale delta (VHD) en France : r\u00e9sultats de l\u2019observatoire de l\u2019h\u00e9patite Delta des p\u00f4les de r\u00e9f\u00e9rences et de l\u2019ANGH."}]},{"@type":"WebSite","@id":"https:\/\/angh.net\/abstracts\/#website","url":"https:\/\/angh.net\/abstracts\/","name":"Abstracts des congr\u00e8s de l&#039;ANGH","description":"Base de donn\u00e9es des abstracts du congr\u00e8s depuis 2003","publisher":{"@id":"https:\/\/angh.net\/abstracts\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/angh.net\/abstracts\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/angh.net\/abstracts\/#organization","name":"ANGH","url":"https:\/\/angh.net\/abstracts\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/","url":"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg","contentUrl":"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg","width":48,"height":18,"caption":"ANGH"},"image":{"@id":"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ANGH-2136322560030484\/"]},{"@type":"Person","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1","name":"abstracts","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g","caption":"abstracts"},"url":"https:\/\/angh.net\/abstracts\/author\/abstracts\/"}]}},"_links":{"self":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts\/1927","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/comments?post=1927"}],"version-history":[{"count":0,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts\/1927\/revisions"}],"wp:attachment":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/media?parent=1927"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/categories?post=1927"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/tags?post=1927"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}